Comparison of serum homocysteine level in Metformin versus glibenclamide treated type 2 DM patients

Iranian Journal of Diabetes and Lipid Disorders

Volumn 4, Issue 2, 2005, Pages

  Omrani, Gholam Hossein Ranjbar ^a   Lari, Omid Bazargan ^a   Mehdizadeh, Ali Reza ^b   Zare, Najaf ^a   Saadat, Nika ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes Mellitus type 2; Glibenclamide; Homocysteine; Metformin

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HOMOCYSTEINE; METFORMIN;

AMINO ACID BLOOD LEVEL; AMPUTATION; ARTICLE; BLINDNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DIABETIC NEUROPATHY; DRUG ACCUMULATION; DRUG EFFECT; FOLIC ACID DEFICIENCY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALABSORPTION; MEAN CORPUSCULAR VOLUME; MEGALOBLASTIC ANEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

EID: 22244487970     PISSN: 17267544     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. King H, Aubert RE, Herman WH. Global Burden of diabetes 1995-2025. Diabetes Care 1998; 21: 1414-31.
2. Nygard O, et al. Total homocysteine and cardiovascular disease. Journal of Internal Medicine 1999; 246: 425-457.
3. Carlsen SM, et al. Metformin increase total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest. 1997 Oct; 57(6): 521-7.
4. Cline GW et al: Imapired glucose transport as a cause of decreased insulin-Stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999; 341: 240.
5. Harris MI et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adult. The third national health and nutrition examination survey 1988-94. Diabetes Care 1998; 21: 518.
6. Wulffele MG et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Journal of Internal Medicine 2003; 254: 455.
7. Seshadri S et al. Plasma homocysteine as risk factor for dementia an Alzheimer's disease. New Engl J Med 2002; 350(20): 2033-41.
8. Joyce BJ et al. Homocysteine Levels and the Risk of Osteoprotic Fracture. New Engl J Med 2004; 3446: 476-83.
9. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. Journal of Internal Medicine 1998; 244(2): 169-74.
10. De Longeril M, et al. Lipid lowering drurgs and homocysteine. Lancet 1999; 353: 209-10.
11. Naurath HJ. effect of vitamin B12, folate, and vitamin B6 supplement in elderly people with normal serum vitamin concentration. Lancet 346 1995 Pages:85-89
12. Nygard O, et al. Major lifestyle determinants of plasma total homocysteine distribution, the hordaland homocysteine study. Am J Clin Nutr 1998; 67: 263-70.
13. Huagsma CJ, et al. Influence of sulfosalazine, methoterexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 79-84.
14. Wouters M, et al. Plasma homocysteine and menopausal status. Euk J Clin Inves 1995; 25: 801-5.
15. Hoogeveen EK, et al. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus, Journal of Internal Medicine 1997; 242: 389-394.
16. th edition.
17. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72.
18. Defronzo RA. Goodman Am and the multicenter metformin study group. Efficacy of metformine in patients with non insulin dependent diabetes mellitus. N Engl J Med 1995; 333: 541-9.